Last reviewed · How we verify

NCT07347093

Reversal of Roux-en-Y Gastric Bypass: A Swedish National Cohort Study

Active, enrolled Last updated 20 January 2026
What this trial tests

trial in Gastric Bypass Surgery in 199 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 November 2025
Primary endpoint
31 March 2026
31 May 2026

Quick facts

Lead sponsorVrinnevi Hospital
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment199
Start date1 November 2025
Primary completion31 March 2026
Estimated completion31 May 2026
Sites1 location across Sweden

Conditions studied

Sponsor

Vrinnevi Hospital

Who can join

18 and older, any sex, with Gastric Bypass Surgery or Revisional Bariatric Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objective: To investigates incidence, indications, symptom relief, complications, and weight outcomes after Roux-en-Y gastric bypass (RYGB) reversal. Background: RYGB is an effective treatment for obesity, but in rare cases may be associated with severe long-term complications requiring RYGB reversal. Evidence on incidence and outcomes is limited. Methods: This nationwide, multi-center, retrospective cohort study included all patients undergoing RYGB reversal in Sweden between 2007 and 2023. Data were obtained from the Scandinavian Obesity Surgery Registry (SOReg) and medical records.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gastric Bypass Surgery

Currently open trials in the same condition.

Other Vrinnevi Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07347093.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing